Mild, reversible pancytopenia induced by rosiglitazone [4]

Diabetes Care

Volumn 28, Issue 6, 2005, Pages 1536-

  Maaravi, Yoram ^a   Stessman, Jochanan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE BESYLATE; HEMOGLOBIN; PHENOXYBENZAMINE; PROPRANOLOL; REPAGLINIDE; ROSIGLITAZONE; SIMVASTATIN;

ADULT; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE COUNT; FOLLOW UP; GLUCOSURIA; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LETTER; LEUKOCYTE COUNT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCYTOPENIA; PATIENT MONITORING; SYMPTOM;

EID: 19944410519     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.6.1536     Document Type: Letter

References (3)

1. Wagstaff AJ, Goa KL: Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62:1805-1837, 2002
2. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941-2948, 2003
3. Benko I, Katayoun D, Csongor A, Zsuga J, Szilvassy Z: Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil. Eur J Pharmacol 477:179-182, 2003